KRAS-mutant
-
BBO-10203, a Novel RAS:PI3Kα Inhibitor, Demonstrates Promising Preclinical Efficacy in KRAS-Mutant Tumors without Hyperglycemia: Data Presented at AACR-NCI-EORTC 2025
BridgeBio Oncology Therapeutics announced positive preclinical data for BBO-10203, a novel compound selectively disrupting the RAS:PI3Kα interaction crucial for KRAS-mutant tumor growth. BBO-10203 inhibits RAS-driven PI3Kα-AKT signaling without causing hyperglycemia. In vivo studies showed oral bioavailability and significant anti-tumor activity, with deep tumor regressions when combined with BridgeBio’s KRAS inhibitors. BBO-10203 is currently in Phase 1 trial (BREAKER-101), and initial Phase 1 clinical data is expected in H1 2026.
